Entry into a Material Definitive Agreement

MINNEAPOLIS, United States and **BRISBANE, Australia 24 September 2026: Anteris Technologies Global Corp.** ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, filed the attached Form 8-K with the U.S. Securities and Exchange Commission (the SEC) on 23 September 2026 US Eastern Time.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR® Transcatheter Heart Valve ("THV"), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Vice Chairman and Chief Executive Officer.

For more information:

Global Investor Relations
investors@anteristech.com
Debbie Ormsby
Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)
mchatterjee@bplifescience.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2026

Anteris Technologies Global Corp.
(Exact name of registrant as specified in its charter)

Delaware	001-42437	99-1407174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302 **9 Sherwood Road** **Toowong, QLD** **Australia**	**4066**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code: +61 7 3152 3200

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	AVR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On September 22, 2026, Anteris Aus Operations Pty Ltd (“AAOPL”), a wholly owned subsidiary of Anteris Technologies Global Corp., and Harvey Industries Group Pty Ltd (“Harvey”, together with AAOPL, the “Parties”), entered into an Amendment (the “Amendment”) to that certain Supply & Quality Agreement, executed May 24, 2024, by and between AAOPL and Harvey (the “Agreement”). The Amendment extends the term of the Agreement for a term expiring on the earlier of (i) December 31, 2026 and (ii) the date of execution of a separate supply and quality agreement between the Parties that is intended to replace the Agreement. All of the other material terms of the Agreement remain unchanged and in full force and effect.

The foregoing description of the Amendment in this Current Report on Form 8-K is only a summary and does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed herewith as Exhibit 10.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.	Description
10.1	First Amendment to Supply & Quality Agreement, between Anteris Aus Operations Pty Ltd and Harvey Industries Group Pty Ltd, dated September 22, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Anteris Technologies Global Corp.
Date: September 23, 2026	By: /s/ Wayne Paterson
	Name: Wayne Paterson
	Title: Vice Chairman and Chief Executive Officer

16 September 2026

Harvey Industries Group Pty Ltd
PO Box 492
Harvey WA 6220

Dear Sir / Madam

Supply & Quality Agreement – Extension of Initial Term

1. We refer to the Supply & Quality Agreement between Anteris Aus Operations Pty Ltd ACN 095 710 339 (**Anteris**) and Harvey Industries Group Pty Ltd ACN 117 597 985 (**Harvey**) (together, the **Parties**) dated 15 May 2024 as supplemented or amended from time to time (**Agreement**).

2. Unless otherwise defined or the context otherwise requires, capitalised terms in this letter not otherwise defined herein have the meaning given in the Agreement.

3. In accordance with clause 8.1 of the Agreement, the Initial Term remained effective until 24 May 2026 and Harvey agreed to supply Anteris under the Agreement for an additional four months from the end of the Initial Term.

4. As contemplated by clause 8.1 of the Agreement, the Parties agree to extend the Initial Term of the Agreement for a Further Term expiring on the earlier of:

   a. 31 December 2026; and

   b. the date on which a further supply and quality agreement between the Parties that is intended to replace the Agreement becomes effective.

5. Clause 11 of the Agreement applies to this letter *mutatatis mutandis*.

6. Please confirm Harvey's agreement to this letter by signing and returning a copy of this letter.

Executed as a deed.

Executed by **Anteris Aus Operations Pty Ltd ACN 095 710 339** in accordance with section 127 of the *Corporations Act 2001* (Cth):

/s/ Wayne Paterson	/s/ David St. Denis David St. Denis (Sep 22, 2026 09:48:45 CDT)
Signature of Director	Signature of Director/Secretary
Wayne Paterson	David St. Denis
Print name of Director	Print name of Director/Secretary

Executed by **Harvey Industries Group Pty Ltd ACN 117 597 985** in accordance with section 127 of the *Corporations Act 2001* (Cth):

/s/ Harvey John Gaynor	/s/ William Campbell Clapin
Signature of Director	Signature of ~~Director/~~Secretary
Harvey John Gaynor	William Campbell Clapin
Print name of Director	Print name of ~~Director/~~Secretary